The world’s first-ever malaria treatment suitable for babies and very young children has been approved for use. Drug manufacturer Novartis has received approval from Swiss authorities for its new malaria drug named Coartem. The development of the drug is very significant, as the overwhelming majority of malaria-related deaths occur in the under-five age group. Following this development, production and distribution of the drug are expected to start in the next few weeks in Africa. Most malaria-related deaths are recorded on the African continent. Malaria accounted for more than half a million deaths worldwide in 2023. Until now, babies were treated with an experimental dosage of the drug meant for older children, putting them at several risks, including overdose and more.